GMP – Page 25 – Pharma.Tips

Inconsistent alignment with WHO TRS during remediation planning – gap remediation roadmap

Addressing Gaps in WHO TRS Compliance During Remediation Planning Pharmaceutical professionals often face significant challenges when aligning their processes with the World Health Organization’s Technical Report Series (WHO TRS), particularly…

Inconsistent alignment with WHO TRS during prequalification preparation – evidence pack for WHO audits

Addressing Inconsistent Alignment with WHO TRS During Prequalification Preparation In the pharmaceutical industry, aligning with the WHO TRS (Technical Report Series) is crucial for securing prequalification (PQ) status. Yet, inconsistencies…

Inefficient CIP cycle during CPV review – inspection-ready cleaning optimization

Improving CIP Cycles During CPV Reviews: A Problem-Solution Approach Cleaning validation plays a critical role in ensuring that pharmaceutical products are manufactured in compliance with Good Manufacturing Practices (GMP). However,…

Documentation not aligned to WHO during internal gap assessment – CAPA aligned to WHO standards

Addressing Documentation Gaps in Alignment with WHO Standards: A Practical Playbook for Pharma Professionals In the ever-evolving landscape of pharmaceutical manufacturing and quality control, alignment with the World Health Organization…

API site WHO GMP risk during API sourcing – avoiding repeat WHO observations

Mitigating Risks in API Sourcing to Ensure WHO GMP Compliance The sourcing of Active Pharmaceutical Ingredients (APIs) often presents challenges that can jeopardize compliance with WHO GMP standards. Frequent failures…

Inadequate WHO GMP training during WHO inspection – WHO inspector expectations explained

Understanding WHO Inspector Expectations for GMP Training Inadequate WHO GMP training during WHO inspection can lead to significant non-compliance issues that jeopardize product quality and regulatory standing. This article serves…

API site WHO GMP risk during remediation planning – avoiding repeat WHO observations

Best Practices for Mitigating API Site WHO GMP Risks During Remediation Planning The pharmaceutical industry faces increasing scrutiny from regulatory bodies like the WHO, FDA, and EMA, particularly in the…

Extended cleaning duration during CPV review – inspection-ready cleaning optimization

Cleaning Duration Optimization During CPV Review: Addressing Inspection Readiness Extended cleaning durations during Cleaning Process Validation (CPV) reviews can lead to operational bottlenecks, increased costs, and potential compliance scrutiny. As…

Inconsistent alignment with WHO TRS during internal gap assessment – WHO inspector expectations explained

Understanding Inconsistent Alignment with WHO TRS During Internal Gap Assessment for Inspection Readiness In pharmaceutical manufacturing, internal gap assessments play a critical role in ensuring compliance with regulatory expectations set…

Inadequate WHO GMP training during WHO inspection – evidence pack for WHO audits

“`html Addressing Inadequate WHO GMP Training for Effective WHO Inspections In the pharmaceutical industry, inadequate training on WHO Good Manufacturing Practices (GMP) can lead to significant non-compliance issues during WHO…

API site WHO GMP risk during prequalification preparation – gap remediation roadmap

Roadmap for Addressing API Site WHO GMP Risks During Prequalification Preparation Prequalification for WHO GMP certification is a rigorous process that can expose various risks within an Active Pharmaceutical Ingredient…

Equipment downtime due to cleaning during equipment changeover – cycle time reduction with compliance assurance

Reducing Equipment Downtime During Changeover Cleaning While Ensuring Compliance In pharmaceutical manufacturing, equipment downtime due to cleaning during equipment changeovers can significantly impact productivity and operational efficiency. Despite maintaining compliance…